3rd Apr 2018 13:49
LONDON (Alliance News) - Silence Therapeutics PLC said Tuesday it has begun patent infringement proceedings in Portugal against Alnylam Pharmaceutical Inc's patisiran product.
On Thursday last week, Alnylam filed a declaratory judgement against Silence, who issued their own suit on Monday.
Silence believes patisiran may infringe its patent EP 1857547 in Portugal, and the next stage of the case will see the Court in Portugal serve the claim on Alnylam.
In the US, Alnylam has filed similar judgements in Boston seeking a finding of non-infringement of Silence's patents in the country, with the complaint not yet filed to Silence.
Chief Executive Ali Mortazavi said: "We reiterate that we will defend the Silence patent estate where we consider third parties to be infringing the company's patent rights.
"As such, in Portugal we consider this process to be important in recognizing the contribution Silence has made to this field. Furthermore, we see Alnylam's filing of a DJ as an acknowledgement of the significance of our patent position."
Shares were down 4.1% on Tuesday at 173.09 pence each.
Related Shares:
SLN.L
